Atria Investments Inc Invests $15.72 Million in Cencora, Inc. (NYSE:COR)

Atria Investments Inc purchased a new position in Cencora, Inc. (NYSE:COR - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 56,534 shares of the company's stock, valued at approximately $15,722,000.

A number of other large investors have also recently made changes to their positions in COR. LPL Financial LLC grew its holdings in Cencora by 7.6% during the 4th quarter. LPL Financial LLC now owns 188,828 shares of the company's stock valued at $42,426,000 after buying an additional 13,417 shares in the last quarter. TIAA Trust National Association boosted its position in shares of Cencora by 1.7% in the fourth quarter. TIAA Trust National Association now owns 73,312 shares of the company's stock valued at $16,472,000 after acquiring an additional 1,204 shares during the period. Meiji Yasuda Asset Management Co Ltd. grew its stake in Cencora by 2.0% during the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,245 shares of the company's stock valued at $1,178,000 after acquiring an additional 105 shares in the last quarter. Korea Investment CORP increased its holdings in Cencora by 5.3% during the 4th quarter. Korea Investment CORP now owns 130,637 shares of the company's stock worth $29,352,000 after acquiring an additional 6,600 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Cencora by 7.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 278,286 shares of the company's stock worth $63,783,000 after purchasing an additional 19,544 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Price Performance

COR stock traded down $5.18 during mid-day trading on Monday, hitting $285.18. 344,619 shares of the stock were exchanged, compared to its average volume of 1,582,535. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52. The business has a fifty day moving average price of $293.31 and a 200 day moving average price of $274.79. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35. The stock has a market capitalization of $55.27 billion, a price-to-earnings ratio of 33.12, a PEG ratio of 1.44 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the company posted $3.80 earnings per share. The company's revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of Cencora stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $294.11, for a total value of $1,461,138.48. Following the completion of the sale, the chief executive officer owned 42,351 shares of the company's stock, valued at approximately $12,455,852.61. The trade was a 10.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total transaction of $4,266,543.26. Following the sale, the chairman owned 309,913 shares of the company's stock, valued at approximately $90,702,237.71. This represents a 4.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,125 shares of company stock valued at $9,993,789. Corporate insiders own 10.80% of the company's stock.

Wall Street Analyst Weigh In

COR has been the topic of several research analyst reports. Bank of America upped their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Morgan Stanley set a $330.00 target price on Cencora and gave the stock an "equal weight" rating in a research report on Wednesday, July 16th. Citigroup boosted their target price on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Finally, Robert W. Baird boosted their target price on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus price target of $309.83.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.